In:
Artificial Organs, Wiley, Vol. 40, No. 10 ( 2016-10), p. 1013-1016
Abstract:
Parathyroid hormone ( PTH ) determination is essential for the diagnosis of renal osteodystrophy, but differences between the laboratory assays can lead to different therapies. This study compared the new T osoh ST AIA ‐Pack Intact PTH assay (Tosoh Bioscience, San Francisco, CA, USA) with the E lecsys I ntact PTH R oche assay (Roche Diagnostics GmbH, Mannheim, Germany), currently considered the gold standard. Nineteen chronic stable hemodialysis patients were enrolled to check PTH levels with the two assays. Median age was 71 years (range 26–84), M / F = 10/9. Blood samples were taken before the start of the same midweek dialysis session. Two blood vacuettes were collected and immediately transported to the central laboratory. The median PTH value was 268 (range 35–901 pg/dL) with the AIA ‐ P ack versus 184 (range 39–552 pg/dL) with E lecsys. The W ilcoxon test showed a significant difference between the two methods ( P 〈 0.0001). AIA ‐ P ack showed a delta value of +38% in comparison with E lecsys and a median bias of 27.4%. For PTH values 〈 150 pg/dL, nine patients were detected with AIA ‐ P ack (47.4%) versus nine patients detected with E lecsys (47.4%). For PTH values between 150 and 300 pg/dL, six patients were detected with AIA ‐ P ack (31.6%) versus four patients with E lecsys (21.0%). For PTH values 〉 300 pg/dL four patients were detected with AIA ‐ P ack (21.0%) versus six patients with E lecsys (31.6%). The two assays showed no differences for each of the three PTH ranges considered. The two PTH assays tested are different and the attending physician should be aware of the differences when patients change their dialysis facility.
Type of Medium:
Online Resource
ISSN:
0160-564X
,
1525-1594
DOI:
10.1111/aor.2016.40.issue-10
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
2003825-2
